13F reference period
Q2 2026
Security Snapshot
Kailera Therapeutics, Inc. - Common Stock, $0.00001 par value (KLRA) Institutional Ownership
CUSIP: 482931102
13F Institutional Holders and Ownership History from Q2 2026 to Q3 2026
Institutions Reporting
100
Shares (Excl. Options)
116.88M
Full value: 116,882,480 · shares · 30 Jun 2026Price
$22.03
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Symbol
- KLRA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 116,882,480
- Total 13F value
- $2,574,896,350
- Portfolio coverage rank
- 0.01%
- Share change
- +115,904,623
- Value change
- +$2,553,397,849
- Number of holders
- 100
- Shares outstanding
- 129,841,205
- SEC-reported price per share
- $10.77
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- KLRA - Kailera Therapeutics, Inc. - Common Stock, $0.00001 par value is tracked under CUSIP 482931102.
- 100 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- The headline uses Q2 2026 reported holdings.
- Quarter-over-quarter comparison is unavailable because the immediately preceding quarter is missing.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 100 institutions filings for Q2 2026.
Security key
482931102
13F reference period
Q2 2026
13F holders
100
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
KLRA full holder history
Kailera Therapeutics, Inc. SEC filings
Kailera Therapeutics, Inc. company facts
Kailera Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 482931102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
KLRA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 8.9% | $238,065,120 | 11,511,853 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 30 Jun 2026 | |||
| RTW INVESTMENTS, LP | 8.3% | $222,864,638 | 10,776,820 | RTW Investments, LP | 30 Jun 2026 | |||
| CANADA PENSION PLAN INVESTMENT BOARD | 5.6% | $151,060,948 | 7,304,688 | CPP Investment Board Private Holdings (4) Inc. | 30 Jun 2026 |
As of 30 Jun 2026,
100
institutional investors reported holding
shares of
Kailera Therapeutics, Inc. - Common Stock, $0.00001 par value (KLRA).
This represents
90%
of the company’s total
outstanding shares.
116.88M
Full value: 116,882,480 · shares · 30 Jun 2026129.84M
Full value: 129,841,205 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bain Capital Investors LLC | 20% | 26,255,581 | 12% | $578,410,449 | |
| Bain Capital Life Sciences Investors, LLC | 17% | 22,583,268 | 30% | $497,509,394 | |
| RTW INVESTMENTS, LP | 8.3% | 10,776,820 | 2% | $237,413,345 | |
| CANADA PENSION PLAN INVESTMENT BOARD | 5.6% | 7,304,688 | 0.09% | $160,922,277 | |
| Atlas Venture Life Science Advisors, LLC | 4% | 5,171,282 | 13% | $113,923,342 | |
| FMR LLC | 3.1% | 3,970,865 | 0% | $87,478,156 | |
| BlackRock, Inc. | 3% | 3,928,604 | 0% | $86,547,146 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.7% | 3,534,410 | 0.01% | $77,864,000 | |
| CITADEL ADVISORS LLC | 2.5% | 3,240,787 | 0.04% | $71,394,538 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.5% | 3,208,286 | 0.1% | $70,678,541 | |
| WELLINGTON MANAGEMENT GROUP LLP | 2.2% | 2,919,110 | 0.01% | $64,307,994 | |
| Royalty Pharma Sub-Manager, LLC | 1.9% | 2,455,357 | 22% | $54,091,515 | |
| Siren, L.L.C. | 1.7% | 2,214,286 | 0.99% | $48,780,721 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.3% | 1,693,958 | 0% | $37,317,895 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3% | 1,652,507 | 0% | $36,404,729 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.87% | 1,133,115 | 0% | $24,968,475 | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 0.85% | 1,100,000 | 0.14% | $24,233,000 | |
| Frazier Life Sciences Management, L.P. | 0.85% | 1,100,000 | 0.53% | $24,233,000 | |
| Trails Edge Capital Partners, LP | 0.76% | 984,786 | 3.4% | $21,694,836 | |
| UBS Group AG | 0.75% | 972,683 | 0% | $21,428,206 | |
| Jupiter Topco LLC | 0.75% | 970,857 | 0% | 0.01% | $21,344,291 |
| STATE STREET CORP | 0.67% | 868,160 | 0% | $19,125,565 | |
| AMERIPRISE FINANCIAL INC | 0.63% | 821,331 | 0% | $18,093,970 | |
| Deep Track Capital, LP | 0.54% | 700,000 | 0.23% | $15,421,000 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.47% | 616,720 | 0.18% | $13,586,342 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Headline period
Q2 2026
Rows shown
1-2 of 2